Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2007 Jun;48(6):585-591. Korean.
    Published online Jun 30, 2007.
    https://doi.org/10.4111/kju.2007.48.6.585
    Copyright © 2007 The Korean Urological Association
    Original Article

    The Characteristics of Prostate Cancer with Metabolic Syndrome in Korean Men

    Byoung Kyu Han, Woo Suk Choi,1 Ji Hyung Yu, Jun Hyun Han, In Ho Chang, Sung Jin Jeong, Sung Kyu Hong, Seok-Soo Byun and Sang Eun Lee
      • Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.
      • 1Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
    • Corresponding author (Email: selee@snubh.org )
    Received February 23, 2007; Accepted April 26, 2007.

    Abstract

    Purpose

    Metabolic syndrome, a concurrence of disturbed glucose and insulin metabolism, overweight, abdominal fat distribution, dyslipidemia, and hypertension, has been reported to have some association with prostate cancer. Here, we assessed the relationship between metabolic syndrome and prostate cancer.

    Materials and Methods

    We assessed a total of 261 men who underwent radical retropubic prostatectomy between January 2004 and May 2005. The patients were stratified into two groups, with metabolic syndrome (n=75) or without (n=186). Metabolic syndrome was defined by the criteria of National Cholesterol Education Program Adult Treatment Panel III. We compared the clinical and pathologic features of specimens between the groups.

    Results

    There was no significant difference between the two groups in terms of mean age, serum prostate specific antigen level, prostate size, Gleason score, and pathologic stage. The tumor volume of prostate cancer was significantly higher in the metabolic syndrome group (6.6±5.5cc vs 5.0±4.5cc, p=0.010). No significant differences were observed in extracapsular extension, seminal vesicle invasion, bladder neck invasion, angiolymphatic invasion, perineural invasion, and multicentricity of cancer between the two groups. As the component of metabolic syndrome increased, the tumor volume was also found to increase (p-value=0.025).

    Conclusions

    The data from our study support that metabolic syndrome is closely associated with the development and progression of prostate cancer.

    Keywords
    Prostate neoplasm; Metabolic syndrome X

    Tables

    Table 1
    Patient characteristics with or without metabolic syndrome (mean±SD)

    Table 2
    Pathologic characteristics with or without metabolic syndrome

    Table 3
    Comparison of age, PSA, prostatectomy Gleason score, and tumor volume according to the finding of metabolic disorder in patients

    Table 4
    Association between prostate cancer characteristics and the number of combined metabolic disorder

    Table 5
    Multivariable analysis affecting tumor volume by linear regression model

    References

      1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. N Engl J Med 2003;348:1625–1638.
      1. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531–1543.
      1. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194–202.
      1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.
      1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–553.
      1. Chung HW, Kim DJ, Jin HD, Choi SH, Ahn CW, Cha BS, et al. Prevalence of metabolic syndrome according to the new criteria for obesity. J Korean Diabetes Assoc 2002;5:431–442.
      1. Kwon HS, Lee HJ, Lee JH, Choi YH, Ko SH. The prevalence and clinical characteristics of the metabolic syndrome in middle-aged Korean adults. Korean J Med 2005;68:359–368.
      1. Renehan AG, Howell A. Preventing cancer, cardiovascular disease, and diabetes. Lancet 2005;365:1449–1451.
      1. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:1646–1650.
      1. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002;3:303–308.
      1. Freedland SJ, Terris MK, Platz EA, Presti JC Jr. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology 2005;66:108–113.
      1. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004;13:47–55.
      1. Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, Thomas G, et al. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005;8:316–320.
      1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary of the third report of the national cholesterol education Program (NCEP). JAMA 2001;285:2486–2497.
      1. Western Pacific Regional Office of the World Health Organization, the International Obesity Task Force. Sydney: Health Communications Australia; 2000. The Asia-Pacific perspective: redefining obesity and its treatment.
        http://www.obesity-asiapacific.com.
      1. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004;266:37–56.
      1. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346–1353.
      1. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005;41:2887–2895.
      1. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate 2005;62:316–321.
      1. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005;103:1092–1095.
      1. Moyad MA. Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective. Urology 2002;59:41–50.
      1. Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 2005;174:919–922.
      1. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CAPSURE. Urology 2005;66:1060–1065.
      1. Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer causes control 2006;17:5–9.
      1. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395–1400.
      1. Nelson BA, Shappell SB, Chang SS, Wells N, Farnham SB, Smith JA Jr, et al. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 2006;97:1169–1172.
      1. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215–244.
      1. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127–137.
      1. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563–566.
    Cited by
    Crossref 3
    Google Scholar 
    Scopus 4
    MeSH Terms
    Abdominal Fat
    Adult
    Cholesterol
    Dyslipidemias
    Education
    Glucose
    Humans
    Hypertension
    Insulin
    Male
    Metabolic Syndrome X
    Metabolism
    Neck
    Neoplasm Grading
    Overweight
    Prostate*
    Prostate-Specific Antigen
    Prostatectomy
    Prostatic Neoplasms*
    Seminal Vesicles
    Tumor Burden
    Urinary Bladder
    Metrics
    Share
    Tables
    slide
    slide
    slide
    slide
    slide

    1 / 5

    PERMALINK